Bavarian Nordic
192.9
DKK
+0.47 %
BAVA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
50 following
+0.47%
+1.45%
-20.22%
+23.18%
+8.71%
+10.23%
-25.66%
+44.16%
+35.24%
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Read moreMarket cap
15.21B DKK
Turnover
109.43M DKK
Revenue
7.06B
EBIT %
21.28 %
P/E
10.05
Dividend yield-%
-
Coverage
Financial calendar
5.3
2025
Annual report '24
9.4
2025
General meeting '24
9.5
2025
Interim report Q1'25
ShowingAll content types
Bavarian Nordic indgår licens- og produktionsaftale omkring mpox-vaccine med Serum Institute of India
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools